Menu
Auditorium Ritz Carlton
REGISTRATION & WELCOME: Christine Mhundwa, International TV Presenter
WELCOME SPEECH H.E. Abdulaziz bin Hamad AlRamaih, Vice Minister of Health, Kingdom of Saudi Arabia
AMR TALKS: Dr. Hanan Balkhy, Regional Director for the Eastern Mediterranean, World Health Organization (WHO)
IN CONVERSATION WITH: Global AMR Champions – What Progress have we made on AMR in 2024?
Moderator: Dr. Hebah Dada, Director of AMR, Public Health Authority, Kingdom of Saudi Arabia
Dr. Muna Abu Sin, Ambassador on AMR, Germany
Dr. Malin Grape, Ambassador on AMR, Sweden
Dr. Amal Saif Al-Maani, Director General of the Disease Surveillance and Control, Ministry of Health, Sultanate of Oman
AMR is an urgent global health and socioeconomic crisis that threatens all age groups in all regions, especially with low- andmiddle-income countries most affected. Whilst still much needs to be accomplished, 2024 marks a pivotal year to find practicalsolutions on how best to tackle the rising challenges from AMR within our food, agriculture and health sectors. Whilst multilateralinstitutions and fora have placed AMR at the heart of global health diplomacy since 2016, the silent shapers and facilitators getunrecognized. This session will emphasise the critical role that nationally appointed AMR directors and envoys play to movepolicy actions into more impact driven solutions.
The Power of Multisectoral Collaboration in Containing AMR by 2030, 2050 & Beyond
Keynote: Dr. Hani Abdulaziz Jokhdar, Deputy Minister for Public Health, Kingdom of Saudi Arabia
Moderator: Dr. Cecilia Mundaca Shah, Associate Vice President for Global Health, UN Foundation
H.E. Dr. Jean Kaseya, Director-General, Africa Centres for Disease Control and Prevention
Dr. Rosena Allin-Khan, Member of Parliament, United Kingdom
Dr. Kenneth Bradley, Global Head of Infectious Disease Discovery, Roche Pharma Research & Early Development
Dr. Nouf Suliman Alnumair, Secretary General, The Ministerial Committee of Health in All Policies (HiAP), Ministry of Health, Kingdom of Saudi Arabia
Dr. Marc Gitzinger, President, BEAM Alliance & CEO BioVersys
AMR is a multidimensional, systems and development challenge. It affects our communities and our economies for now and thefuture. We need effective coordination mechanisms to assure sustainable participations of all stakeholders within and outside agovernment. Whilst most countries have adopted national action plans for AMR, what is often missing, is a programmatic aspectthat implements different interventions, through cross-sectoral coordination. This panel will take stock of examples of successfulmultisectoral coordination. The panel will discuss how an effective and robust response to AMR, requires intersectionality and awhole-of society approach to ensure effective implementation mechanisms for evidence-based AMR policy interventions that include all industries and sectors.
Best Practice from KSA – The Multisectoral AMR Committee in the Kingdom
Keynote: Dr. Abdullah Assiri, Assistant Deputy Minister for Preventive Health, Kingdom of Saudi Arabia
Moderator: Dr. Hail Al-Abdely, Consultant of Infectious Disease; First Chairman of the AMR Committee
Dr. Hebah Dada, Director of AMR, Public Health Authority, Kingdom of Saudi Arabia
Dr. Sanad Alharbi, Head of The Animal Health Sector at The National Center for The Prevention and Control of Plant Pests and Animal Diseases, Weqaa, Kingdom of Saudi Arabia
Prof. Ahmed Al-Jedai, Assistant Deputy Minister for Medical Support, Ministry of Health, Kingdom of Saudi Arabia
Prof. Fars Alanazi, CEO, Saudi National Institution of Health
The Kingdom of Saudi Arabia has created the first cross-ministerial and departmental National AMR Committee in 2017. With thetrue reflection of a One Health approach represented within the Committee, Saudi Arabia has successfully championed AMR asone of its global health priorities prominently since its G20 Presidency in 2020. This panel will reflect on the creation and journeyof the National AMR Committee and share best practice and impact stories related to successful IPC policies and national actionplan implantation strategies. The national action plans lay out the variety of resources required by a nation to tackle AMR,including economic issues that disincentivise the development of replacement products by pharmaceutical corporations, aflagship stewardship program development of a case for sustainable investments and effective prevention.
Youth AMR Awareness Campaign Video
Announcement Sadim Alhayli, Head of Strategic Partnerships for AMR, Ministry of Health, Kingdom of Saudi Arabia
Presented by the Quadripartite Working Group on Youth Engagement Randa Bazzi, Nahashon Gicheru, Marina Ungurenci
Containing AMR through Public Private Partnerships, Raising Awareness &
Promoting Action via Patient Groups, Community Leaders & Non-Traditional Influencers
Keynote: Dr. Nahar Alazmi, CEO Saudi Health Council
Moderator: Dr. Nour Shamas, The AMR Narrative, WHO Task Force of AMR Survivors
Dr. Ramanan Laxminarayan, President, One-Health Trust
Najat Mokhtar, Deputy Director General, International Atomic Energy Agency IAEA
Dr. Hosam Zowawi, Associate Professor, Clinical Microbiology, KSAUHS
Dr. Sujith J Chandy, CEO, ICARS
Julian Nyamupachitu, Deputy Director, ReAct Africa
2024 marked a pivotal moment to address the issues of AMR across the health, economic, and societal dimensions. There is aneed for partnership, collaboration, and unity to create metrics and collate data that go beyond human health and look at theecosystem impact of AMR and a need to explore modalities for enhancing a meaningful whole-of-society approach and socialparticipation, not involving only policymakers. Best practice sharing, learning, and capacity building are some of the keycomponents of tackling AMR, so international engagements between public and private partners, policymakers, internationalorganizations, patients’ associations, and non-traditional actors can instigate awareness, support socio-economic behavioural change through the One Health approach and explore real-world solutions that have a sustained impact in containing AMR. This panel will showcase the work that is being conducted in community, patient groups and civil society to help create a more integrated bridge between society, industry and policymakers.
LUNCH BREAK
Deep Dive into Diagnostics – The Testing Case for AMR
In Conversation with: Ministerial Perspectives- addressing Dx gaps for AMR: High-Level Panel Discussion
Moderator: Dr. Ayoade Alakija, Board Chair, FIND
Dr. Ethel Maciel, Vice Minister of Health, Brazil, Minister of Health Brazil
DISCUSSION: Response from Implementation Partners
Moderator: Dr. Ayoade Alakija, Board Chair, FIND
Dr. Hanan Balkhy, Regional Director for the Eastern Mediterranean, WHO
Dr. Ifedayo Adetifa, CEO, FIND
Dr. Reem Bunyan, Executive Director, Global Innovation Hub
PANEL: Getting Practical- What concrete actions are being taken and who is doing what to address Dx gaps for AMR, to support the implementation of NAPs and the Diagnostics Resolution
Moderator: Dr. Ifedayo Adetifa, CEO, FIND
Earl Gast, CEO and President, URC
Guido Sander, Regional Head, Roche Diagnostics
Dr. David Ripin, Executive Vice President, Clinton Health Access Initiative
Muhieddine Makkouk, Vice President, KSA, Cepheid
Diane Flayhart, Director, Global Public Health, Becton Dickinson
Prof. Ahmed Albarraq, Chief Officer of Public Health Laboratories, Public Health Authority
Diagnostics are critical to tackling AMR. Diagnostic tests are critical to understanding the type of infection a patient has and therefore how best to treat it, supporting both good stewardship of antimicrobials and ensuring appropriate treatment. The Lancet Commission on Diagnostics found that nearly half (47%) of the people in the world have little or no access to diagnostic tests. In this side event, hosted by FIND (Foundation for Innovative New Diagnostics), participants will discuss pathways to implement commitments to closing diagnostics gaps for AMR. These discussions aim to identify priority innovations and actions needed to close the diagnostics gaps in different country settings, and how these might be financed and implemented through public priv ate partnerships.
BREAKOUT SESSIONS: ONE-HEALTH BREAK-OUT SESSIONS & TECHNICAL EXPERTS
BREAKOUT SESSION 1: A Broken Market and Innovation Pipeline – A Simulation Exercise by the G20 Global AMR R&D Hub
PRESENTER: Ralf Sudbrak, Deputy Director, G20 AMR R&D Hub
KEYNOTE: Prof. Mohsen Naghavi, IHME, University of Washington
INTERVENTIONS: Prof. Kevin Outterson, CEO, CARB-X;
Dr. Peter Beyer; Deputy Executive Director, GARDP;
Prof. Sabiha Essack, University of Kwazulu-Natal, South African Research Chair in Antibiotic Resistance & One Health, South Africa;
Dr. Reem Al Bunyan, Executive Director of the G20 Global Innovation Hub for Improving Value in Health;
Dr. Marc Gitzinger, President, BEAM Alliance & CEO BioVersys
The urgent need to boost research and development (R&D) of the tools, strategies and products addressing AMR has been acknowledged at the highest political levels. Most recently, G7, G20 and other high-level fora have reiterated their commitment to strengthen support for R&D and bring new antimicrobials to market, whilst preserving access for those most in need and ensuring they are used with care. The 2024 G7 Progress Report by the Global AMR R&D Hub and WHO has outlined the global financial landscape for antibacterial innovation, tracking country-by-country progress and highlighting key actions for the coming year to drive sustainability and equity in the innovation ecosystem. With limited resources and funds, prioritisation of efforts addressing the most critical unmet health needs will be key. Building on the most recent data and evidence on investments in R&D and the socio-economic impact of AMR, globally and regionally, this interactive breakout session will convene key stakeholders to jointly explore and simulate real-world solutions in policy, funding and cross-sector collaboration to accelerate the discovery, supply, use and accessibility of antimicrobials addressing the most critical public health needs.
BREAKOUT SESSION 2: Operating models of the Regional Antimicrobial Access & Logistics Hub
PRESENTER: Abdulrhman Mohana, Director of AMR, Public Health Authority, Kingdom of Saudi Arabia
KEYNOTES: Fahad Al Shebel, CEO, NUPCO
Dr. Meraee Al-Qahtani, Assistant Deputy of Supply Chain, Ministry of Health, Kingdom of Saudi Arabia
INTERVENTIONS: Moderator: Dr. Ahmed Al-Jedai, Assistant Deputy Minister, Pharmaceutical Services, Ministry of Health, Kingdom of Saudi Arabia
Dr. Ramanan Laxminarayan, President, One-Health Trust,
George Richards, Director Community Jameel; Derrick Sim, Interim Chief Vaccine Programmes and Markets Officer, Gavi,
Dr. Alexandra Cameron, Senior Expert, and Unit Head A.I. of Impact Initiatives and Research Coordination, WHO AMR Division,
Julian Nyamupachitu, Deputy Director, ReAct Africa
Antibiotics, when used appropriately, save lives. Each year, an estimated 7.7 million people die of bacterial infections – 203,000 of them being newborns with sepsis. The recent Lancet series on Sustainable Access to Effective Antibiotics showed that an estimated 750,000 of bacterial-infection related deaths are preventable by improving access to prevention – through vaccination, infection prevention and control and better water, sanitation and hygiene. However, the largest number of deaths can be prevented through better access to quality antibiotics – both existing and novel ones. One of the Outcomes of the 4th Ministerial is the establishment of an Antimicrobial Access and Logistics Hub in the region. The Hub will not only ensure timely delivery of antimicrobial countermeasures in the country and the region but opens up opportunities for collaboration to improve access to vital antimicrobials in LMICs. To realize this opportunity, the Kingdom has taken stock of exiting initiatives, suc h as the Global Dr.ug Facility for TB, the SECURE initiative launched by the WHO and GARD-P as well as PAHO; and has begun to exchange experience with key stakeholders of these initiatives. This parallel session will explore possible operation models of the proposed Hub, including challenges of last mile delivery, funding and approaches to stewardship to ensure appropriate use of antibiotics.
BREAKOUT SESSION 3: The AMR One Health Learning Hub – A Saudi & Global Best Practice
PRESENTER: Dr. Hebah Dada, Director of AMR, Public Health Authority, Kingdom of Saudi Arabia
KEYNOTES: Dr. Pasi Penttinen, MD MPH PhD, CEO, Gulf Center for Disease Prevention and Control
Prof. Aws bin Ibrahim Al-Shamsan, Secretary General of the Saudi Commission for Health Specialties
INTERVENTIONS: Dr. Muhannad Aloraini, Director of Public Health Academy KSA,
Dr. Adham Rashad Ismail Abdel-Moneim, WHO Representative,
Dr. Javier Yugueros Marcos, Head of AMR and Veterinary Products Department, WOAH,
Dr. Randa Bazzi, Co-Founder, One Health Alliance Jordan & Member, Quadripartite Working Group on Youth Engagement for AMR,
Dr. Junxia Song, Senior Animal Health Officer, AMR, Zoonotic Disease, One Health, FAO
The Learning Hub will be housed in the facilities of the Public Health Academy in Riyadh, Saudi Arabia; its initial reach is proposed to be regional with the aim of creating a global community of practice. The focus lies on practical implementation and a One Health approach. Training and best practice modules will be offered virtually, using a variety of digital tools and media, and in person in the rooms and training labs of the KSA Public Health Academy, synergizing efforts with the existing One Health learning and knowledge-sharing platforms and initiatives. It will serve equally as a training and as an exchange platform, ensuring that national contexts and specific local challenges are considered. The format for best practice sharing will be developed o ver time, considering feedback from participant and implementation partners and based on the impact the training has on progress of design and implementation of National Action Plans (NAPs). The Hub will offer hands-on training, including in the field as applicable, that is tailored to support implementation of multi-sectoral NAPs, such as methods to collect, aggregate and manage data to contribute to the national AMR surveillance and antimicrobial consumption reports to inform policies and regulations as well as global databases, including GLASS, ANIMUSE and INFARM.
COFFEE BREAK
IN CONVERSATION WITH: Appropriate Use of Future Proof Antimicrobials
Moderator: Dr. Abdullah bin Rashoud Algwizani, CEO, Public Health Authority, Kingdom of Saudi Arabia
Dr. Ali Tala Asiri, Director General, Saudi Patient Safety Centre
Dr. Abdullah bin Rashoud Algwizani, CEO, Public Health Authority, Kingdom of Saudi Arabia
Michael Craige, Director of Antimicrobial Resistance Coordination and Strategy Unit, Center for Disease Control and Prevention, USA
Antibiotics play a crucial role in modern medicine and without them many treatments and procedures carry a significantly higher risk of complication or failure. To contain AMR, behavioural change around antimicrobial use across human, veterinary and plant health is needed, together with sustained investments in Research & Development (R&D) to develop novel and innovative antimicrobials and diagnostic tools and frameworks to ensure equitable access to safe and effective “workhorse” antimicrobial s. This conversation aims to take stock of the current landscape of antimicrobials in the supply chain and provides recommendations on how to adjust regulation, market incentives and cross-sectorial to ensure a safe end-to-end access to antimicrobials
Announcement – AMR Initiative: Dr. Khalid Adnan Nasser Alburikan, Ministry of Health, Advisor Biotechnology & Innovation, Kingdom of Saudi Arabia
PANEL 4: The Future Economic Impact of AMR & Sustainable Financing Initiatives in Containing AMR for the Health of our Ecosystem
Presentation: Dr. Javier Guzman, Director of Global Health Policy and Senior Fellow, Centre for Global Development (CGD) & Anthony McDonnell, Policy Fellow, CGD
Moderator: Mr. Rakan Bin Dohaish, Assistant Deputy Minister for International Collaboration, Ministry of Health, Kingdom of Saudi Arabia
Dr. Henry Skinner, CEO, AMR Action Fund
Dr. Kevin Outterson, CEO, CARBX
Dr. Maria Larsson Ortino, Senior Global ESG Manager Asset Management, LGIM
Magnus Lindelow, Global Program Lead for Pandemic PPR and Public Health, World Bank
Dr. Javier Guzman, Director of Global Health Policy and Senior Fellow, CGD
Governments all around the world and international institutions were not financially equipped to address the health crisis of our century. Despite COVID-19 no longer being deemed as an international public health emergency of international concern, an investment gap lingers between potential needs and current funding for global and public health systems which includes the costs incurred by people’s rising resistances to antimicrobials. According to the latest CGD report – if countries fail to act on AMR – the global economic output would decrease by US$1.7 trillion by 2050, affecting all aspects of the economic ecosystem from hospital costs to tourism and hospitality. At the same time, analysis such as from the OECD suggest that by 2035, resistance to “third-line antimicrobials” could more than double in OECD countries compared to the 2005 levels, exponentially affecting quality of life and survival rates. This panel will discuss the cost of inaction by governments and cross-sectoral actors in containing AMR. The panel will assess socioeconomic benefits in investing in high quality treatment and funding to promote new antimicrobials that could boost the global economy by US$ 960 billion by 2050. The panel will explore how to address this disparity, creating mechanisms that incentivize the development and distribution of antibiotics in regions that are often marginalized in healthc are access. Panellists will make the economic case for investment and showcase the return of investment argument in measures containing AMR and how best to incentivize the adoption of effective measures and stimulate innovation.
PANEL 5: The Road to Affordable & Quality Antimicrobials – Lessons Learnt from COVID-19 & What Next?
Moderator: James Anderson, Executive Director, Global Health, IFPMA
Dr. Bruce Altevogt, Vice President, Public Health Policy and Strategic Engagement, Biomerieux
Laurent Muschel, Director General, Health Emergency Preparedness and Response Authority (HERA)
Dr. Arshnee Moodley, Leader CGIAR Antimicrobial Resistance Hub & AMR Team Lead, International Livestock Research Institute in Nairobi, Kenya.
Dr. Anand Anandkumar, CEO, Bugworks
Dr. Alexander Pym, Director of Infectious Disease, Wellcome Trust
The COVID-19 pandemic presented an unprecedented challenge to health systems globally, highlighting the need for strengthened health systems and improved models of innovation, including for antimicrobial products. In the UN High Level Meeting Declaration on AMR commitments to improve availability, affordability and quality of health products were made with the aim to improve equitable access and regulation. This panel aims to explore how lessons learned from Covid can be applied to antimicrobial resistance and how actors from different sectors can work together to ensure that all patients that need them have access to antimicrobial products and these products are used appropriately in humans and in animals
KEYNOTE & CLOSING SPEECH
H.E. Abdulaziz Hamad AlRamaih, Assistant Deputy Minister for International Collaboration, Ministry of Health, Kingdom of Saudi Arabia
SOCIAL PROGRAMME & WELCOME EVENING (ALL GUESTS)
Copyright 2024 © AMR | All rights reserved